Butyrylcholinesterase in metabolic syndrome

Medical Hypotheses

Volumn 75, Issue 6, 2010, Pages 648-651

  Sridhar, Gumpeny R ^a   Rao, Allam Appa ^b   Srinivas, Kudipudi ^c   Nirmala, Gumpeny ^a   Lakshmi, Gumpeny ^d   Suryanarayna, Dasika ^e   Nageswara Rao, Padmanabhuni V ^f   Kaladhar, Dowluru ^f   Kumar, Sali Veeresh ^f   Devi, Tatavarthi Uma ^f   Nitesh, Turaga ^g   Hanuman, Thota ^h  

^a Endocrine and Diabetes Centre   (India)

^b JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

^c Pydah College   (India)

^d KASTURBA MEDICAL COLLEGE   (India)

^e SHRI VISHNU ENGINEERING COLLEGE FOR WOMEN   (India)

^f GITAM UNIVERSITY   (India)

^g SRM UNIVERSITY   (India)

^h DMS SVH College of Engineering   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AATF PROTEIN; ADENOSINE TRIPHOSPHATASE; ALDEHYDE DEHYDROGENASE; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE 1; ATP6VOA2 PROTEIN; CHAT PROTEIN; CHOLINESTERASE; DF ALDH9A1 PROTEIN; NUCLEOTIDE; PDHX PROTEIN; PROTEIN; PSME3 PROTEIN; UBE21 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ARTICLE; BIOCHEMISTRY; BIOINFORMATICS; COGNITION; COMPUTER MODEL; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; FOLLOW UP; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MOLECULAR DOCKING; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHYLOGENETIC TREE; PREDICTION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE;

AMINO ACID SEQUENCE; ANIMALS; BUTYRYLCHOLINESTERASE; CATALYTIC DOMAIN; CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; HUMANS; METABOLIC SYNDROME X; MICE; PHYLOGENY; PROTEIN BINDING;

ANIMALIA;

EID: 77958477932     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2010.08.008     Document Type: Article

References (48)

1. Patocka J., Kuca K., Jun D. Acetylcholinesterase and butyrylcholinesterase - important enzymes of human body. Acta Med 2004, 47:215-228.
2. Sridhar G.R., Nirmala G. Inborn errors in lipid metabolism. Lipid disorders 2002, 59-80. Association of Physicians of India. API College of Physicians. B.B. Tripathy, S. Das (Eds.).
3. Mahmoud F.F., Haines D.D., Abul H.T., Omu A.E., Abu-Donia M.B. Butyrylcholinesterase activity in gestational diabetes: correlation with lymphocyte subpopulations in peripheral blood. Am J Reprod Immunol 2006, 56:185-192.
4. Mahmoud F.F., Abul H.T., Haines D.D., Omu A.E., Diejomaoh M., Wise J.A., et al. Butyrylcholinesterase activity and lymphocyte subpopulations in peripheral blood of Kuwaiti women experiencing recurrent spontaneous abortion. J Reprod Immunol 2008, 77:186-194.
5. Hubbard R.E., O'Mahony M.S., Calver B.L., Woodhouse K.W. Plasma esterases and inflammation in ageing and frailty. Eur J Clin Pharmacol 2008, 64:895-900.
6. Paraoanu L.E., Steinert G., Klaczinski J., Becker-Rock M., Bytyqi A., Layer P.G. On functions of cholinesterases during embryonic development. J Mol Neurosci 2006, i30:201-204.
7. Margalit R.C., Adler B., Abramson J.H., Gofin J., Kark J.D. Butyrylcholinesterase activity, cardiovascular risk factors, and mortality in middle-aged and elderly men and women in Jerusalem. Clin Chem 2006, 52:845-852.
8. Valle A., O'Connor D.T., Taylor P., Zhu G., Montgomery G.W., Slagboom P.E., et al. Butyrylcholinesterase: association with the metabolic syndrome and identification of 2 gene loci affecting activity. Clin Chem 2006, 52:1014-1020.
9. Sridhar G.R., Nirmala G., Apparao A., Madhavi A.S., Sreelatha S., Rani J.S., et al. Serum butyrylcholinesterase in type 2 diabetes mellitus: a biochemical and bioinformatics approach. Lipids Health Dis 2005, 4:18.
10. Abott C.A., Mackness M.I., Kumar S., Olukoga A.O., Gordon C., Arrol S., et al. Relationship between serum butyrylcholinesterase activity, hypertriglyceridemia and insulin sensitivity in diabetes mellitus. Clin Sci 1993, 85:7-81.
11. Iwasaki T., Yoneda M., Nakajima A., Terauchi Y. Serum butyrylcholinesterase is strongly associated with adiposity, the serum lipid profile and insulin resistance. Intern Med 2007, 46:1633-1639.
12. Alcantara V.M., Oliveira L.C., Rea R.R., Suplicy H.L., Maia E.A.C.F. Butyrylcholinesterase activity and metabolic syndrome in obese patients. Clin Chem Lab Med 2005, 43:285-288.
13. Kutty K.M., Payne R.H. Serum pseudocholinesterase and very-low-density lipoprotein metabolism. J Clin Lab Anal 1994, 8:247-250.
14. Rustemeijer C., Shouten J.A., Voerman H.J., Beynen A.C., Donker A.J., Heine R.J. Is pseudocholinesterase activity related to markers of triacylglycerol synthesis in type II diabetes mellitus?. Clin Sci 2001, 101:29-35.
15. Randell E.W., Mathews M.S., Zhang H., Seraj J.S., Sun G. Relationship between serum butyrylcholinesterase and the metabolic syndrome. Clin Biochem 2005, 38:799-805.
16. Hashim Y., Shepherd Dd., Wiltshire S., Holman R.R., Levy J.C., Clark A., et al. Variant on chromosome 3q is associated with Type II diabetes in white Caucasian subjects. Diabetologia 2001, 44:2227-2230.
17. Randell E.W., Rogers B., Smith E. Production of butyrylcholinesterase by caco-2 cells: lack of relationship with triglyceride production. Cell Mol Life Sci 2001, 58:1327-1332.
18. Van Lith H.A., Beynen A.C. Dietary cholesterol lowers the activity of butyrylcholinesterase (EC 3.1.1.8) but elevates that of esterase-1 (EC3.1.1.1) in plasma of rats. Br J Nutr 1993, 70:721-726.
19. Duysen E.G., Li B., Lockridge O. The butyrylcholinesterase knockout mouse a research tool in the study of drug sensitivity, bio-distribution, obesity and Alzheimer's disease. Expert Opin Drug Metab Toxicol 2009, 5:523-528.
20. Garcia C, Berre JJPL, Bordier L, Dupuy O, Mayaudon H, Banduceau B. Place of serum butyrylcholinesterase activity in the evaluation of cardiovascular risk in diabetic patient. ADA Abstracts; 2008: 2248 PO.
21. Manoharan I., Boopathy R., Darvesh S., Lockridge O. A medical health report on individuals with silent butyrylcholinesterase in the Vysya community of India. Clin Chim Acta 2007, 378:128-135.
22. Janson J., Laedtke T., Parisi J.E., Brien P.O., Petersen R.C., Butler P.C. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004, 53:474-481.
23. Biessels G.J., Kappalle L.J. Uhrecht diabetic encephalopathy study group. Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology?. Biochem Soc Trans 2005, 33:1041-1044.
24. Johansen A., Nielsen E.-M.D., Andersen G., Hamid Y.H., Jensen D.P., Glümer C., et al. Large-scale studies of the functional K variant of the butyrylcholinesterase gene in relation to Type 2 diabetes and insulin secretion. Diabetologia 2004, 47:1437-1441.
25. Sridhar G.R., Hanuman T., Appa Rao A., Suresh Babu C., Siva Prasad A., Divakar Ch. Alzheimer's disease and Type 2 diabetes mellitus: the cholinesterase connection?. Lipids Health Dis 2006, 5:28.
26. Raygani A.V., Zahrai M., Soltanzadeh A., Doosti M., Javadi E., Pourmotabbed T. Analysis of association between butyrylcholinesterase K variant and apolipoprotein E genotypes in Alzheimer's disease. Neurosci Lett 2004, 371:142-146.
27. Nicolls M.R. The clinical and biological relationship between Type II diabetes mellitus and Alzheimer's disease. Curr Alzheimer Res 2004, 1:47-54.
28. Vionnet N., Hani E.H., Dupont S., Gallina S., Francke S., Dotte S., et al. Genome wise search for type 2 diabetes susceptibility genes in French Whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2 diabetes locus on chromosome 1q21-q24. Am J Hum Genet 2000, 67:1470-1480.
29. Greig N.H., Utsuki T., Ingram D.K., Wang Y., Pepeu G., Scall C., et al. Selective butyrylcholinesterase inhibition elevated brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc Natl Acad Sci 2005, 102:17213-17218.
30. Lehmann D.J., Johnston C., Smith A.D. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. Hum Mol Genet 1997, 6:1933-1936.
31. Stefanello F.M., Franzon R., Tagliari B., Wannmacher C., Wajner M., Wyse A.T. Reduction of butyrylcholinesterase activity in rat serum subjected to hyperhomocystinemia. Metab Brain Dis 2005, 20:97-103.
32. Houstis N., Rosen E.D., Lander E.S. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006, 440:944-948.
33. Sun M.K., Alkon D.L. Links between Alzheimer's disease and diabetes. Drugs today (Barc) 2006, 42:481-489.
34. Grossman H. Does diabetes protect or provoke Alzheimer's disease? Insights into the pathobiology and future treatment of Alzheimer's disease. CNS Spectr 2003, 8:815-823.
35. Craft S., Reger M.A., Baker L.D. Insulin resistance in Alzheimer's disease - a novel therapeutic target. Alzheimer's disease and related disorders annual 5 2006, 111-133. Taylor and Francis, London. S. Gauthier, P. Scheltens, J.L. Cummings (Eds.).
36. Rao A.A., Siva Reddy C., Sridhar G.R., Annapurna A., Hanuman T., Prameela M., et al. Enhanced butyrylcholinesterase activity may be the common link in triggering low-grade systemic inflammation and decrease in cognitive function in diabetes mellitus and Alzheimer's disease. Curr Nutr Food Sci 2008, 4:213-216.
37. Rao A.A., Sridhar G.R., Das U.N. Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer's disease. Med Hypotheses 2007, 69:213-216.
38. Sridhar G.R., Lakshmi P.V., Appa Rao A. Phylogenetic tree construction of butyrylcholinesterase sequences in life forms. J Assoc Physicians India 2006, 54:122-123.
39. Pezzementi L., Chatonnet A. Evolution of cholinesterases in the animal kingdom. Chem Biol Interact 2010, 187:27-33.
40. Sridhar G.R., Venkata P. Sleep and body weight in diabetes mellitus: a large retrospective analysis from South India. Diab Res Clin Pract 2006, 72:209-211.
41. Sridhar G.R., Lakshmi G. Sleep & obesity. J Gen Med 2009, 21:54-56.
42. Kang J.E., Lim M.M., Bateman R.J., Lee J.J., Smyth L.P., Cirrito J.R., et al. Amyloid-β dynamics are regulated by orexin and the sleep-wake cycle. Science 2009, 326:1005-1007.
43. Tong W., Williams R.J., Wei Y., Murga L.F., Ko J., Ondrechen M.O. Enhanced performance in prediction of protein active sites with THEMATICS and support vector machines. Prot Sci 2008, 17:333-341.
44. Chikhi A., Bensegueni Docking efficiency comparison of Surflex, a commercial package and Arguslab, a licensable freeware. J Comput Sci Syst Biol 2008, 1:81-86.
45. Li Z., Wan H., Shi Y., Ouyang P. Personal experience with four kinds of chemical structure software: review of ChemDraw, ChemWindow, ISIS/Draw and Chemsketch. J Chem Inf Comput Sci 2004, 44:1886-1890.
46. Appa Rao A., Srinivas K., Rajender R., Das U.N. Prediction of butyrylcholinesterase function through domain analysis and protein-protein interaction. Curr Nutr Food Sci 2008, 4:176-184.
47. Cibicková L., Palicka V., Cibicek N., Cermáková E., Micuda S., Bartošová L., et al. Differential effects of statins and alendronate on cholinesterases in serum and brain of rats. Physiol. Res. 2007, 56:765-770.
48. Kamal M., Tan Y., Seale J.P., Qu X. Targeting BuChE-inflammatory pathway by SK0506 to manage type 2 diabetes and Alzheimer disease. Neurochem Res 2009, 34:2163-2169.